Document Detail


Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity.
MedLine Citation:
PMID:  21831035     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Stearoyl-CoA desaturase 1 (SCD-1) is the rate-limiting enzyme that catalyses the conversion of saturated to monounsaturated fatty acids. Increased SCD-1 expression and activity has been implicated in cancer, cardiovascular diseases, insulin resistance and obesity. Studies with humans, wild-type rodents, knock-out mice and cells in culture show that SCD-1 inhibition decreases lipogenesis and increases GLUT4-mediated glucose uptake in skeletal muscle. In this review, we will evaluate the role of SCD-1 as a homeostatic check-point between glucose and fatty acid metabolism in the development and progression of obesity. In addition to the role of SCD-1 in glucose and fatty acid metabolism, we will also discuss the expression and regulation of SCD-1, its specific interactions with inflammatory responses and PPARs, the role of SCD-1 derived MUFAs in obesity and the relevance of SCD desaturation index as a predictor of obesity and metabolic syndrome. Additionally, we will explore the prospects of SCD-1 as a potential drug target for the management of obesity and related disorders.
Authors:
Hemant Poudyal; Lindsay Brown
Related Documents :
11807975 - Abietic acid inhibits lipoxygenase activity.
21696905 - Targeted and non-targeted metabolic time trajectory in plasma of patients after acute c...
10574665 - Dietary conjugated linoleic acid reciprocally modifies ketogenesis and lipid secretion ...
22260735 - Lactic acid production in saccharomyces cerevisiae is modulated by the expression of th...
6333415 - Biochemical and cellular identification of hla-bw44 subtypes.
16349325 - Effects of sieving, storage, and incubation temperature on the phospholipid fatty acid ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Endocrine, metabolic & immune disorders drug targets     Volume:  11     ISSN:  1871-5303     ISO Abbreviation:  Endocr Metab Immune Disord Drug Targets     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269157     Medline TA:  Endocr Metab Immune Disord Drug Targets     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  217-31     Citation Subset:  IM    
Affiliation:
School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia. Lindsay.Brown@usq.edu.au.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  5'-adenosine monophosphate-activated protein kinase and the metabolic syndrome.
Next Document:  Role of ?3 Longchain Polyunsaturated Fatty Acids in Reducing Cardio-Metabolic Risk Factors.